You are here

About Pompe Disease

Pompe disease (also known as glycogen storage disease type II [GSDII], acid maltase deficiency or GAA deficiency) is an autosomal recessive inherited disorder caused by a mutation in the gene encoding GAA.Deficiency in GAA affects lysosomal-mediated degradation of glycogenesis and results in intralysosomal accumulation of glycogen and disruption of the tissue architecture in various organs, most notably the skeletal muscles, heart and liver.2


As is the case with other LSDs, Pompe disease presents at different ages and with differing degrees of severity. Pompe disease is classified into two broad categories – infantile and late onset disease – based on age of onset.3

Age of onset, organ involvement and disease severity correlate with residual enzyme activity and genotype – enzyme activity is absent or minimal in infantile disease, but may be reduced to varying degrees (residual enzyme activity 3-30%) in those with late-onset disease.4

Early age of onset (within the first months of life) is associated with more severe disease with a shorter survival time. In the infantile-onset form symptoms become apparent within the first few months of life and prognosis is poor such that most patients die within the first year or two of life without treatment.Patients with classic infantile-onset Pompe disease are further distinguished based on their cross reactive immunological material (CRIM) status – CRIM-negative patients lack any form of endogenous GAA, whereas CRIM-positive patients are able to synthesize some catalytically inactive GAA.6

Late-onset Pompe disease generally has a milder phenotype than infantile-onset disease; it can present with symptoms any time after age 1 year.It is characterised by skeletal myopathy usually in a limb-girdle distribution, and is associated with less cardiac involvement and a more protracted disease course, but eventually leads to respiratory failure.8,9  The term pseudodeficiency is used to describe patients who have low GAA enzyme activity but who do not develop Pompe disease.4


Epidemiological data for Pompe disease has been derived from gene frequency studies, evaluation of anonymous dried blood spots and population-based screening programs. Based on calculated carrier frequencies the combined incidence of infantile-onset and late-onset Pompe disease was previously estimated to be 1:40,000.18 More recent data from the US, based on analyses of dried blood spots, indicates an incidence of approximately 1:28,000. Data from the USA estimate the prevalence of pseudodeficiency to be <1%.5

Common mutations associated with infantile-onset disease have been detected in people of African descent (c.2560C>T; p.ARg85Ter), Taiwanese (c.1935C>A; p.Asp645Glu) and Dutch (c.del525T; p.Glu176ArgfsTer45 and exon 18 deletion) populations,10 such that incidence rates may vary from 1:14,000 to 1:600,000, depending on the geographic area or ethnic group being examined.Due to the autosomal recessive inheritance, both genders are equally affected.

Pooled data from population based studies (USA and Austria) and the Taiwanese newborn screening program estimate that 28% of Pompe disease cases are infantile-onset and that 85% of these have associated cardiomyopathy (classic infantile-onset Pompe disease).About 25% of cases of classic infantile-onset Pompe disease are CRIM-negative, which is associated with worse outcomes.

Incidence of Pompe disease in different populations. 

Population Incidence
African American 1:14,000
Netherlands 1:40,000 combined
1:138,000 infantile-onset
1:57,000 late onset
US 1:40,000 combined
South China/Taiwan 1:50,000
European descent 1:100,000 infantile-onset onset
1:60,000 late-onset onset
Australia 1:145,000
Portugal 1:600,000

Adapted from Leslie and Tinkle, GeneReviews (2013)10


GAA is a lysosomal enzyme responsible for hydrolyzing α-1,4- and α-1,6-glycosidic bonds in glycogen, maltose and isomaltose.Lysosomes are a cell’s disposal system.11 Thus, a deficiency in the GAA enzyme leads to the accumulation of normal glycogen in lysosomes and the cytoplasm. This leads eventually to tissue destruction, and enlargement and dysfunction of involved organs.

Electron microscopy examination of individual myocytes from patients with classical infantile-onset Pompe disease has demonstrated a pathogenic cascade that can be divided into several stages.12

Pompe disease pathogenic cascade. 

Adapted from Al Jasmi et al. BMC Neurology (2015) 15:205

In the past decade it has become apparent that this relatively simplistic view of Pompe disease pathophysiology is inadequate. Autophagy – a process in which the cell’s cytoplasm and organelles are sequestered in a double-membrane bound vesicle – facilitates recycling of amino acids, fatty acids and glucose during periods of stress and starvation.11 Several autophagic pathways have been described, of which macroautophagy is of most relevance to Pompe disease.GAA deficiency results in a secondary defect in the fusion between autophagasomes and lysosomes; as a result, autophagosomes accumulate leading to muscle tissue damage.13-16

As research continues to look for new therapeutic approaches to Pompe disease, its complex pathological cascade continues to be elucidated. Current understanding is that it may also involve disturbance of calcium homeostasis, mitochondrial abnormalities, dysfunctional autophagy, accumulation of toxic nondegradable materials, and accelerated production of lipofuscin deposits that are unrelated to ageing.17




Pompe disease is caused by mutations of the gene encoding lysosomal acid α-glucosidase (GAA), located on chromosome 17q25.2-q25.3, and is inherited as an autosomal recessive trait.1

Clinical Impacts

Clinical Impacts

Clinically, Pompe disease presents as a wide spectrum of symptoms and phenotypes from the classical form (early onset, severe phenotype) to a non-classical form (later onset, milder phenotype).1



Pompe disease is named after Joannes Cassianus Pompe, who first described a case of idiopathic hypertrophy of the heart in a 7-month old infant in the Netherlands in 1932, noting massive vacuolar glycogen accumulation not only in the heart but and in all tissues examined.1


  1. 1.Hirschhorn R, Reuser AJ. Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency [Internet]. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G. eds. . New York, NY: McGraw-Hill Medical. 2015 [cited 17/12/2015]. Available here
  2. 2.Angelini C, Nascimbeni AC, Semplicini C. Therapeutic advances in the management of Pompe disease and other metabolic myopathies. Ther Adv Neurol Disord. 2013;6:311-21.
  3. 3.Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32:751-76, ix.
  4. 4.van der Ploeg AT, Reuser AJJ. Pompe's disease. The Lancet. 2008;372:1342-53.
  5. 5.Kemper AR. The Condition Review Workgroup. Evidence Report: Newborn Screening For Pompe Disease. 2013. [cited 17/12/2015] Available here.
  6. 6.van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38:305-14.
  7. 7.Manganelli F, Ruggiero L. Clinical features of Pompe disease. Acta Myol. 2013;32:82-4.
  8. 8.Herzog A, Hartung R, Reuser AJ, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7:35.
  9. 9.Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.
  1. 10.Leslie N, Tinkle BT. Glycogen Storage Disease Type II (Pompe Disease). In: Pagon RA, Adam MP, Ardinger HH, al e, editors. GeneReviews® [Internet]. 1993-2015. Seattle (WA): : University of Washington, Seattle; 2013 [Updated 2013]. Available from:
  2. 11.Zirin J, Nieuwenhuis J, Perrimon N. Role of autophagy in glycogen breakdown and its relevance to chloroquine myopathy. PLoS Biol. 2013;11:e1001708.
  3. 12.Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006;86:1208-20.
  4. 13.Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem. 1998;273:19086-92.
  5. 14.Raben N, Baum R, Schreiner C, et al. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy. 2009;5:111-3.
  6. 15.Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 2007;26:45-8.
  7. 16.Shea L, Raben N. Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S42-7.
  8. 17.Lim JA, Kakhlon O, Li L, Myerowitz R, Raben N. Pompe disease: Shared and unshared features of lysosomal storage disorders. Rare Dis. 2015;3:e1068978.
  9. 18.Ausems MGEM, Verbiest J, Herman MMP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. European Journal of Human Genetics. 1999; 7: 713-716